Brain Tumor Diagnosis And Therapeutics Industry

The global brain tumor diagnosis and therapeutics market size is expected to reach USD 4.94 billion by 2030, registering a CAGR of 7.1% during the forecast period, according to a new report by Grand View Research, Inc. The market is expected to pose lucrative growth over the forecast period, owing to the increasing incidence of various brain cancers, particularly glioblastoma, coupled with the rising geriatric population.

Increasing Public-Private Partnerships (PPPs) in the health sector, which are modernizing diagnostic imaging and radiology services, are supporting the expansion of this industry. Emerging technologies like Sodium Magnetic Resonance Imaging(²³Na MRI), Positron Emission Tomography (PET), and Chemical Exchange Saturation Transfer (CEST) are used to detect the response of brain tumors in multicenter clinical trial settings. In addition, these technologies are helpful in quantitatively imaging tumor response to therapies, thereby promoting their use during treatment.

These technologies have the potential to extend MRI beyond anatomical imaging by providing information on physiology and cellular metabolism, thereby increasing the efficiency of diagnosis. Hence, the market is expected to witness productive growth over the forecast period.

Moreover, ongoing research in molecular diagnostics to understand cell biology at the cellular level of malignancy and identification of gene mutations associated with malignancy is anticipated to significantly contribute toward the growth of the industry.

On the other hand, the high cost of diagnosing brain tumors, which ranges from USD 450 to 12,200, is likely to hinder the growth of the global brain tumor diagnosis market.

Gather more insights about the market drivers, restrains and growth of the Global Brain Tumor Diagnosis And Therapeutics market

Brain Tumor Diagnosis And Therapeutics Market Segments Highlights:

• CT scan segment dominated the market with a revenue share of 25.6% in 2023 and is also likely to grow at a significant rate during the forecast period
• Targeted therapy segment drives market growth through its improved efficiency, reduced side effects, resistance mitigation capabilities, and advances in molecular profiling techniques, and expected to register a CAGR of 7.7% in the forecast period.
• North America is expected to dominate the brain tumor diagnosis and therapeutics market, owing to developed healthcare infrastructure coupled with rising awareness regarding advanced technologies amongst the population in this region. In addition, increasing consumer disposable income supported by healthcare insurance and reimbursement policies in the U.S. is expected to spur growth.

Brain Tumor Diagnosis And Therapeutics Market Report Segmentation

Grand View Research has segmented the global brain tumor diagnosis and therapeutics market report based on type, product, diagnosis, therapeutics, end-use, and region:

Brain Tumor Diagnosis And Therapeutics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Primary
  • Meningioma
  • Gliomas
  • Astrocytomas
  • Pituitary Tumors
  • Others
• Secondary

Brain Tumor Diagnosis And Therapeutics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Stains & Varnishes
• Shellacs
• Lacquers
• Others

Brain Tumor Diagnosis And Therapeutics Diagnosis Outlook (Revenue, USD Million, 2018 - 2030)

• MRI
• CT-Scan
• Tissue Sampling
• PET-CT Scan
• Cerebral Arteriogram
• Lumbar Puncture
• Molecular Testing
• EEG
• Others

Brain Tumor Diagnosis And Therapeutics Therapeutics Outlook (Revenue, USD Million, 2018 - 2030)

• Surgery
• Radiation Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Others

Brain Tumor Diagnosis And Therapeutics End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals
• Oncology Treatment Centers
• Others

Brain Tumor Diagnosis And Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Brain Tumor Diagnosis And Therapeutics Company Insights

• Amgen Inc.
• AstraZeneca
• Bayer AG
• GE HealthCare
• Hoffmann-La Roche Ltd
• Eisai Co., Ltd
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Shimadzu Corporation
• Siemens Healthineers AG

Order a free sample PDF of the Brain Tumor Diagnosis And Therapeutics Market Intelligence Study, published by Grand View Research.